Compare MS & MRK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MS | MRK |
|---|---|---|
| Founded | 1924 | 2000 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Bankers/Brokers/Service | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 342.1B | 317.8B |
| IPO Year | 2025 | 1997 |
| Metric | MS | MRK |
|---|---|---|
| Price | $184.33 | $140.66 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 26 | 27 |
| Target Price | ★ $211.05 | $159.76 |
| AVG Volume (30 Days) | 4.6M | ★ 6.5M |
| Earning Date | 10-14-2026 | 10-29-2026 |
| Dividend Yield | ★ 2.56% | 2.34% |
| EPS Growth | ★ 28.43 | 8.01 |
| EPS | ★ 6.90 | N/A |
| Revenue | $34,275,000,000.00 | ★ $65,011,000,000.00 |
| Revenue This Year | $17.08 | $3.14 |
| Revenue Next Year | $5.13 | $4.31 |
| P/E Ratio | $26.08 | ★ N/A |
| Revenue Growth | ★ 5.73 | 1.31 |
| 52 Week Low | $152.80 | $82.01 |
| 52 Week High | $232.25 | $157.00 |
| Indicator | MS | MRK |
|---|---|---|
| Relative Strength Index (RSI) | 42.14 | 41.64 |
| Support Level | $178.95 | $111.05 |
| Resistance Level | $192.31 | $154.46 |
| Average True Range (ATR) | 4.78 | 4.41 |
| MACD | 0.60 | -0.27 |
| Stochastic Oscillator | 48.71 | 8.20 |
Morgan Stanley is a massive global financial services firm, with offices in 42 countries and more than 82,000 employees as of year-end 2025. The firm cut its teeth in investment banking and institutional trading, where it maintains a strong presence today, but generates the lion share of its income from wealth and asset management franchises, where it boasted $9.3 trillion in client assets at the end of 2025. After reincorporation as a bank holding company in the wake of the global financial crisis, Morgan Stanley also boasts a top 10 banking franchise by deposits, with more than $400 billion in customer deposits, predominately attributable to cash sweeps from its wealth management and brokerage businesses.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform, led by Keytruda, is a major contributor to overall sales. The company also has a substantial vaccine business aimed at preventing pediatric diseases, as well as Gardasil for human papillomavirus. Additionally, Merck sells animal health-related drugs. From a geographical perspective, 47% of the company's sales are generated from US human health (pharmaceuticals and vaccines).